» Articles » PMID: 39542916

[EyeMatics-Multicenter Data Evaluation of Real-world Data with Interoperable Medical Informatics]

Abstract

The evaluation of real-world data (RWD) enables insights to be gained from a wide range of patient data collected in routine clinical practice. In addition, multicenter analyses represent a broad and representative patient population and have the potential to capture the actual treatment situation. As a basis for this, the definition of datasets and an infrastructure for data exchange is necessary. Data integration centers (DIC) have already been established at (university) hospitals throughout Germany in order to extract RWD for scientific analyses from the various source systems and integrate them into research-compatible data infrastructures. The project described here aims to demonstrate the added value of this data integration using a case of application in ophthalmology, defining a core dataset as an ophthalmology extension module and establishing a cross-site data exchange infrastructure. As a first step, the treatment success of eye diseases treated with intravitreal injection (IVI) should be improved. To achieve this goal a dashboard for clinical data is provided that clearly visualizes the merged data. Furthermore, algorithms will be developed to identify new imaging biomarkers that can be used for treatment monitoring and predict treatment outcomes.

References
1.
Augustin A, Bopp S, Fechner M, Holz F, Sandner D, Winkgen A . Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN (0.19 mg fluocinolone acetonide implant). Eur J Ophthalmol. 2019; 30(2):382-391. PMC: 7079293. DOI: 10.1177/1120672119834474. View

2.
Bathelt F, Reinecke I, Peng Y, Henke E, Weidner J, Bartos M . Opportunities of Digital Infrastructures for Disease Management-Exemplified on COVID-19-Related Change in Diagnosis Counts for Diabetes-Related Eye Diseases. Nutrients. 2022; 14(10). PMC: 9147678. DOI: 10.3390/nu14102016. View

3.
Bertelmann T, Feltgen N, Scheffler M, Hufenbach U, Wiedon A, Wilhelm H . Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study. Health Qual Life Outcomes. 2016; 14(1):132. PMC: 5029004. DOI: 10.1186/s12955-016-0536-1. View

4.
Bulirsch L, Sassmannshausen M, Nadal J, Liegl R, Thiele S, Holz F . Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2021; 106(9):1288-1294. PMC: 9411904. DOI: 10.1136/bjophthalmol-2020-318672. View

5.
Callizo J, Ziemssen F, Bertelmann T, Feltgen N, Vogeler J, Koch M . Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study. Clin Ophthalmol. 2019; 13:2167-2179. PMC: 6847987. DOI: 10.2147/OPTH.S209253. View